MedPath

Recorlev

These highlights do not include all the information needed to use RECORLEV safely and effectively. See full prescribing information for RECORLEV. RECORLEV (levoketoconazole) tablets, oral Initial U.S. Approval: 1981 (ketoconazole)

Approved
Approval ID

d4c5fead-bc4a-fb02-e053-2a95a90ae4fc

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 16, 2023

Manufacturers
FDA

Xeris Pharmaceuticals, Inc.

DUNS: 609377135

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Levoketoconazole

PRODUCT DETAILS

NDC Product Code72065-003
Application NumberNDA214133
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateDecember 7, 2021
Generic NameLevoketoconazole

INGREDIENTS (1)

LEVOKETOCONAZOLEActive
Quantity: 150 mg in 1 1
Code: 2DJ8R0NT7K
Classification: ACTIB

Drug Labeling Information

BOXED WARNING SECTION

LOINC: 34066-1Updated: 6/30/2023

WARNING: HEPATOTOXICITY AND QT PROLONGATION

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Recorlev - FDA Drug Approval Details